

2023 Regular Session

SENATE BILL NO. 14

BY SENATOR BERNARD

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROL DANGER SUBSTANCE. Provides relative to schedules of the Uniform Controlled Dangerous Substances Law. (8/1/23)

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through

3 (8), (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6), to enact

4 R.S. 40:964(Schedule I)(A)(100), (C)(69) through (80), and (E)(14) through (16),

5 (Schedule IV)(B)(58), and (Schedule V)(D)(7), and to repeal R.S. 40:964(Schedule

6 IV)(C), relative to the Uniform Controlled Dangerous Substances Law; to add certain

7 substances to Schedules I, IV, and V; to remove substances from Schedule IV; to

8 provide for updated structural language; and to provide for related matters.

9 Be it enacted by the Legislature of Louisiana:

10 Section 1. R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1) through (8),

11 (12), (17) through (22), and (24) through (29) and (Schedule V)(D)(6) are hereby amended

12 and reenacted and R.S. 40:964(Schedule I)(A)(100), (C)(69) through (80), and (E)(14)

13 through (16), (Schedule IV)(B)(58), and (Schedule V)(D)(7) are hereby enacted to read as

14 follows:

15 §964. Composition of schedules

16 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.

17 40:962, consist of the following drugs or other substances, by whatever official

1 name, common or usual name, chemical name, or brand name designated:

2 SCHEDULE I

3 A. Opiates. Unless specifically excepted or unless listed in another schedule,
4 any of the following opiates, including their isomers, esters, ethers, salts, or salts of
5 isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,
6 or salts is possible within the specific chemical designation:

7 * * *

8 **(100) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)**
9 **piperazin-1-yl]-1-phenylpropan-2-ol)**

10 * * *

11 C. Hallucinogenic substances. Unless specifically excepted or unless listed
12 in another schedule, any material, compound, mixture, or preparation, which
13 contains any quantity of the following hallucinogenic substances, or which contains
14 any of their salts, isomers, or salts of isomers, whenever the existence of such salts,
15 isomers, or salts of isomers is possible within the specific chemical designation, for
16 purposes of this Paragraph only, the term "isomer" includes the optical, position, and
17 geometric isomers:

18 * * *

19 **(69) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)**
20 **methanone (other name: FUB-144)**

21 **(70) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-**
22 **carboxamide (other names: 5F-CUMYL-PINACA; SGT-25)**

23 **(71) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide**
24 **(other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-**
25 **FLUOROBENZYL))**

26 **(72) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-**
27 **dimethylbutanoate (other name: 5F-EDMB-PINACA)**

28 **(73) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,**
29 **3-dimethylbutanoate (other names: 5F-MDMB-PICA; 5F-MDMB-2201)**

* * *

(iii) By substitution at the 2-amino nitrogen atom with alkyl, cycloalkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

* * *

(8) Naphthylpyrovalerone whether or not further substituted ~~in~~ on the naphthyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further substituted ~~in~~ on the naphthyl ring by one or more other univalent substituents or whether or not further substituted ~~in~~ on the carbon chain at the 3, 4, or 5 position with an alkyl substituent.

* * *

(14) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid)

(15) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate)

(16) Methiopropamine (N-methyl-1-(thiophen-2-yl)propane-2-amine)

F. Synthetic cannabinoids. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following individual compounds or chemical groups, or any of those individual compounds or groups which contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible within the specific compounds or chemical groups:

(1) Adamantoylindoles: any compound containing a 3-(1-adamantoyl)indole structure, whether or not further substituted ~~in~~ on the indole ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any extent.

(2) Adamantylamidoindoles: Any compound containing a N-(adamantyl)-1H-

1 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole
2 ring to any extent or whether or not substituted ~~in~~ on the adamantyl ring to any
3 extent.

4 (3) Benzoylindoles: any compound containing a 3-(benzoyl)indole structure,
5 whether or not substituted ~~in~~ on the indole ring to any extent or whether or not
6 substituted on the phenyl ring to any extent.

7 (4) Benzylolecarboxamides: Any compound containing a
8 N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~
9 on the indole ring or whether not substituted on the phenyl ring to any extent.

10 (5) Butaldehydeamidoindoles: Any compound containing a
11 N-(1-oxobutan-2-yl)-1H-indole-3-carboxamide structure, with or without substitution
12 ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide,
13 ~~alkylarylhalide, cycloalkylmethyl,~~ arylalkylhalide, cycloalkylmethyl,
14 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide,
15 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
16 tetrahydropyranylmethyl group, whether or not further substituted on the
17 butaldehyde group to any extent.

18 (6) Cumylindolecarboxamides: Any compound containing a
19 N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without
20 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
21 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ arylalkylhalide, cycloalkylmethyl,
22 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide,
23 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
24 tetrahydropyranylmethyl group, whether or not further substituted on the phenyl
25 group to any extent.

26 (7) Cyclohexylphenols: any compound containing a 2-(3-
27 hydroxycyclohexyl)phenol structure, whether or not substituted ~~in~~ on the cyclohexyl
28 ring to any extent or whether or not substituted on the phenyl ring to any extent.

29 (8) Cyclopropanoylindoles: any compound containing a 3-

1 (cyclopropanoyl)indole structure, whether or not substituted ~~in~~ on the indole ring to
2 any extent or **whether or not substituted on** the cyclopropyl ring to any extent.

3 * * *

4 (12) Hexahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
5 ring system **to any extent** except where contained in cannabis or cannabis resin.

6 * * *

7 (17) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole
8 structure, whether or not substituted ~~in~~ on the indole ring to any extent or **whether**
9 **or not substituted on** the naphthyl ring to any extent.

10 (18) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole
11 structure, whether or not substituted ~~in~~ on the pyrrole ring to any extent or **whether**
12 **or not substituted on** the naphthyl ring to any extent.

13 (19) Naphthylamidoindoles: any compound containing a N-(naphthyl)-1H-
14 indole-3-carboxamide structure, whether or not further substituted ~~in~~ on the indole
15 ring to any extent or whether or not substituted ~~in~~ on the naphthyl ring to any extent.

16 (20) Naphthylindolecarboxylates: Any compound containing a
17 naphthyl-1H-indole-3-carboxylate structure, whether or not further substituted ~~in~~ on
18 the indole ring or **whether or not substituted on** the naphthyl ring to any extent.

19 (21) Naphthylmethylenes: any compound containing a 1-(1-
20 naphthylmethyl)indene structure, whether or not substituted ~~in~~ on the indene ring to
21 any extent or **whether or not substituted on** the naphthyl ring to any extent.

22 (22) Naphthylmethylinindoles: any compound containing a 1-H-indol-3-yl-(1-
23 naphthyl)methane structure, whether or not substituted ~~in~~ on the indole ring to any
24 extent or **whether or not substituted on** the naphthyl ring to any extent.

25 * * *

26 (24) Phenylacetylindoles: any compound containing a 3-phenylacetylindole
27 structure, whether or not substituted ~~in~~ on the indole ring to any extent or **whether**
28 **or not substituted on** the phenyl ring to any extent.

29 (25) Phenylindolecarboxamides: Any compound containing a

1 N-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted ~~in~~
2 on the indole ring or **whether or not substituted on** the phenyl ring to any extent.

3 (26) Phenylpropionaldehydeamidoindoles: Any compound containing a
4 N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without
5 substitution ~~in~~ on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl
6 halide, ~~alkylarylhalide, cycloalkylmethyl,~~ **arylalkylhalide, cycloalkylmethyl,**
7 cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, **halide,**
8 morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a
9 tetrahydropyranylmethyl group, whether or not further substituted on the
10 phenylpropionaldehyde group to any extent.

11 (27) Quinolinyndolecarboxamides: Any compound containing a N-
12 quinoliny-1H-indole-3-carboxamide or N-isoquinoliny-1H-indole-3-carboxamide
13 structure, whether or not further substituted ~~in~~ on the indole, quinoline or the
14 isoquinoline ring to any extent.

15 (28) Quinolinyndolecarboxylates: any compound containing a
16 quinolin-8-yl-1H-indole-3-carboxylate or isoquinolin-8-yl-1H-indole-3-carboxylate
17 structure, whether or not further substituted ~~in~~ on the indole, quinoline, or
18 isoquinoline ring to any extent.

19 (29) Tetrahydrodibenzopyrans whether or not substituted ~~in~~ on the tricyclic
20 ring system **to any extent** except where contained in cannabis or cannabis resin.

21 * * *

22 SCHEDULE IV

23 * * *

24 B. Depressants.

25 Unless specifically excepted or unless listed in another schedule, any
26 material, compound, mixture, or preparation containing any quantity of the following
27 substances, including its salts, isomers, and salts of isomers, whenever the existence
28 of such salts, isomers, and salts of isomers is possible within the specific chemical
29 designation:

1 * * *

2 **(58) Daridorexant**

3 * * *

4 SCHEDULE V

5 * * *

6 D. Depressants. Unless specifically exempted or excluded or unless listed in
7 another schedule, any material, compound, mixture, or preparation which contains
8 any quantity of the following substances having a depressant effect on the central
9 nervous system, including its salts:

10 * * *

11 (6) ~~Pregalin~~ **Pregabalin**

12 **(7) Ganaxolone (3- α -hydroxy-3- β -methyl-5- α -pregnan-20-one)**

13 * * *

14 Section 2. R.S. 40:964(Schedule IV)(C) is hereby repealed.

15 Section 3. The Louisiana State Law Institute is hereby authorized and directed to
16 renumber the substances in R.S. 40:964(Schedule I)(A), (C), and (E), (Schedule IV)(B), and
17 (Schedule V)(D) to ensure that the substances are in alphabetical order.

The original instrument and the following digest, which constitutes no part
of the legislative instrument, were prepared by Brandi Cannon.

DIGEST

SB 14 Original

2023 Regular Session

Bernard

Present law provides for the designation of controlled dangerous substances into Schedules I, II, III, IV, and V based upon the substances' potential for addiction and abuse.

Proposed law adds 16 additional substances to Schedule I.

Proposed law adds Daridorexant to Schedule IV and removes Fenfluramine.

Proposed law adds Ganaxolone to Schedule V.

Proposed law updates the structural language for stimulants and synthetic cannabinoids in Schedule I.

Effective August 1, 2023.

(Amends R.S. 40:964(Schedule I)(E)(1)(i) and (iii) and (8) and (F)(1)-(8), (12), (17)-(22), and (24)-(29) and (Schedule V)(D)(6); adds R.S. 40:964(Schedule I)(A)(100), (C)(69)-(80), and (E)(14)-(16), (Schedule IV)(B)(58), and (Schedule V)(D)(7); repeals R.S. 40:964(Schedule IV)(C))